|
|
 |
INDIA-PHARMACEUTICAL-GILEAD-HEPATITIS
Gregg Alton, Executive Vice President for Corporate and Medical Affairs at Gilead Sciences, addresses a press conference in New Delhi on September 15, 2014. US biotechnology firm Gilead Sciences announced September 15 that it has signed generic licensing deals with seven India-based companies to increase access to its Hepatitis C drugs in the developing world. The non-exclusive agreements allow the companies to make the drug sofosbuvir, known as Sovaldi that is sold at the cost of $1,000 a tablet in the United States, for distribution in 91 developing countries, the company said in a statement. AFP PHOTO/ SAJJAD HUSSAIN
|
|
|
|
Detalii fotografie |
| Loc: |
|
NEW DELHI, INDIA |
|
| Sursa: |
|
AFP / Mediafax Foto |
|
| Fotograf: |
|
SAJJAD HUSSAIN |
|
| Data: |
|
15 Septembrie 2014 |
|
| Dimensiuni: |
|
2486 x 3315 (1.15 MB) |
|
|
|
|
|
|